-
2 weeks ago | 
ajmc.com | Brooke McCormick |John Heymach
In part 2 of an interview conducted at the American Association for Cancer Research Annual Meeting 2025, John Heymach, MD, PhD, chair of the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center and lead investigator of the phase 1A/1B Beamion LUNG-1 trial (NCT04886804), discusses the impact of zongertinib, a HER2-targeted tyrosine kinase inhibitor, on subgroups of patients with advanced, previously treated HER2-mutated non–small cell lung...
-
2 weeks ago | 
ajmc.com | Brooke McCormick |John Heymach
John Heymach, MD, PhD, chair of the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center and lead investigator of the phase 1A/1B Beamion LUNG-1 trial (NCT04886804), shares data from the study, which he presented today at the American Association for Cancer Research Annual Meeting 2025 in Chicago.
-
Oct 4, 2024 | 
nature.com | Junya Fujimoto |Andrew Futreal |John Heymach |Jia Huang Wu |Christopher I. Amos |Jianjun Zhang
AbstractLung Cancer remains the leading cause of cancer deaths in the USA and worldwide. Non-small cell lung cancer (NSCLC) harbors high transcriptomic intratumor heterogeneity (RNA-ITH) that limits the reproducibility of expression-based prognostic models.
-
Sep 25, 2024 | 
nature.com | John Heymach
AbstractNon-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years.
-
Sep 9, 2024 | 
onclive.com | John Heymach
CommentaryVideoSeptember 9, 2024Author(s):Fact checked by:John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer. John V.
-
Aug 20, 2024 | 
nature.com | John Heymach
Correction to: Nature Medicine https://doi.org/10.1038/s41591-018-0007-9, published online 23 April 2018. In the version of the article initially published, in Supplementary Fig. 7c, the ERK1/2 blot (afatinib treatment) was flipped with respect to the drug concentration. The corrected version is shown below as Fig. 1. The blots shown in Supplementary Fig. 10d were a repeat of the experiment and have now been corrected to show the membranes that correspond to Supplementary Fig. 7c.
-
Jun 25, 2024 | 
onclive.com | John Heymach
John Heymach, MD, PhD, professor, chair, David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from an exploratory subgroup analysis of the phase 3 AEGEAN trial (NCT03800134), which evaluated perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) and baseline N2 lymph node...
-
May 19, 2023 | 
onclive.com | John Heymach
AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLCExpert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.
-
May 3, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel |John Heymach |Jorge Nieva
Source/Disclosures
Source:
Heymach JV, et al. Abstract CT005. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.
Disclosures:
AstraZeneca sponsored this study.
-
Apr 17, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel |John Heymach
Source/Disclosures
Source:
Heymach JV, et al. Abstract CT005. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.
Disclosures:
AstraZeneca sponsored this study.
